Servier India Launches Biomarker Testing Initiative for Cancer Diagnosis

• Servier India , the Indian arm of the French biopharmaceutical company Servier , has launched a biomarker testing initiative aimed at improving early and precise diagnosis of Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA) . The initiative, developed in partnership with MedGenome and Strand Life Sciences , seeks to expand access to molecular testing across India and promote precision oncology through subsidised and free diagnostic services.

Expanding Access to Molecular Diagnostics

• The programme aims to bridge the diagnostic accessibility gap between urban and rural regions by making biomarker testing for AML and CCA available at affordable or no cost . The collaboration will focus on testing for critical mutations—particularly IDH1 and IDH2 —which are essential for guiding targeted therapies. Under this scheme, patients treated in government hospitals will receive these mutation tests free of cost , ensuring equitable access to advanced cancer diagnostics.

Precision Oncology and Early Detection

• Servier India emphasised that early and accurate genetic testing significantly improves patient outcomes by enabling oncologists to personalise treatments. Molecular profiling helps clinicians select targeted therapies, monitor resistance patterns, and improve survival rates. The initiative aligns with India’s growing shift toward precision medicine , integrating genomic insights into cancer care to enhance the standard of treatment.

Collaborative and Holistic Approach

• The success of the programme depends on collaboration between diagnostic laboratories, clinicians, and healthcare networks to ensure timely delivery of results and early treatment initiation. The project operates under ‘Servier Care’ , Servier India’s comprehensive patient-support programme , which offers financial assistance, subsidised diagnostics, and access to innovative therapies.

Exam Pointers

• Partners: Servier India, MedGenome, Strand Life Sciences

• Focus cancers: AML and Cholangiocarcinoma

• Free testing: IDH1/IDH2 mutations for government-sector patients

• Programme: Part of Servier Care initiative

• Goal: Expand precision oncology and equitable access to molecular testing

Outlook

This initiative marks a major step toward accessible and inclusive precision oncology in India. By leveraging partnerships and technology, Servier India aims to strengthen early diagnosis, improve treatment outcomes, and advance the nation’s oncology care ecosystem.